On May 20, 2025 Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, reported that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety and efficacy of an investigational combination therapy with MHB039A, a PD-1xVEGF bispecific antibody, and MHB036C, a TROP-2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC) (Press release, Minghui Pharmaceutical, MAY 20, 2025, View Source;combination-study-of-pd-1xvegf-bispecific-and-trop-2-adc-in-advanced-nsclc-302460254.html [SID1234653258]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MHB039A is a novel bispecific antibody targeting PD-1 and VEGF. It demonstrated full blocking activities against both PD-1 and VEGF with superior PD-1 activity compared to competitor antibodies. In a completed Phase Ⅰ dose-escalation study, MHB039A was well-tolerated at doses up to 30 mg/kg, with no DLTs observed and the MTD not reached. The safety profile was consistent with that of previously reported PD-1xVEGF bispecifics. Robust PD-1 receptor occupancy and VEGF biomarker responses were observed across all dose levels. Encouraging anti-tumor activity was noted in NSCLC patients who had progressed after prior PD-1 inhibitor and chemotherapy treatment.
MHB036C is a novel antibody-drug conjugate targeting TROP-2, developed using Minghui’s proprietary SuperTopoi ADC platform. In ongoing Phase 1/2 studies, MHB036C has been evaluated in 138 patients with advanced or metastatic solid tumors. The ADC has demonstrated a favorable safety profile, with no major hematologic adverse events and ILD. Promising anti-tumor activity has been observed in heavily pre-treated NSCLC and breast cancer patients.
"We are excited to initiate this Phase Ⅱ trial investigating the combination therapy with MHB039A and MHB036C in advanced NSCLC," said Guoqing Cao, Ph.D., Chief Executive Officer of Minghui Pharmaceutical. "Emerging clinical data increasingly support the potential of combining ADCs with immuno-oncology (I/O) agents to achieve more robust and durable anti-tumor responses across multiple solid tumors. We believe these combinations will play a pivotal role in reshaping the standard-of-care treatment paradigms. Our PD-1xVEGF bispecific antibody offers a promising new backbone for I/O-based combination therapies."
Dr. Cao added, "This trial underscores our strategic focus on developing ADCs and PD-1xVEGF bispecific combination therapies and establishes a strong foundation for extending this approach to other solid tumors, including breast cancer."